RESUMO
Final-year medical students at UK universities are able to do elective placements elsewhere, to learn about other health care systems. We chose Cuba because of its excellent health outcomes despite relatively few resources. We were struck, for instance, when Cuba made global headlines in 2015 as the first country to eliminate mother-to-child transmission of HIV and syphilis. And, since the UK's underfunded National Health Service is experiencing high demand and increasing pressure, we sought to understand more about Cuba's socialist health system, where health care spending per capita is much lower than the UK's, but life expectancy is almost the same.
Assuntos
Comunicação , Cultura , Atenção à Saúde/organização & administração , Intercâmbio Educacional Internacional , Estudantes de Medicina , Cuba , Atenção à Saúde/métodos , Humanos , Reino Unido/etnologiaRESUMO
OBJECTIVES: The aim of this study was to estimate lowest possible treatment costs for four novel cancer drugs, hypothesising that generic manufacturing could significantly reduce treatment costs. SETTING: This research was carried out in a non-clinical research setting using secondary data. PARTICIPANTS: There were no human participants in the study. Four drugs were selected for the study: bortezomib, dasatinib, everolimus and gefitinib. These medications were selected according to their clinical importance, novel pharmaceutical actions and the availability of generic price data. PRIMARY AND SECONDARY OUTCOME MEASURES: Target costs for treatment were to be generated for each indication for each treatment. The primary outcome measure was the target cost according to a production cost calculation algorithm. The secondary outcome measure was the target cost as the lowest available generic price; this was necessary where export data were not available to generate an estimate from our cost calculation algorithm. Other outcomes included patent expiry dates and total eligible treatment populations. RESULTS: Target prices were £411 per cycle for bortezomib, £9 per month for dasatinib, £852 per month for everolimus and £10 per month for gefitinib. Compared with current list prices in England, these target prices would represent reductions of 74-99.6%. Patent expiry dates were bortezomib 2014-22, dasatinib 2020-26, everolimus 2019-25 and gefitinib 2017. The total global eligible treatment population in 1â year is 769â 736. CONCLUSIONS: Our findings demonstrate that affordable drug treatment costs are possible for novel cancer drugs, suggesting that new therapeutic options can be made available to patients and doctors worldwide. Assessing treatment cost estimations alongside cost-effectiveness evaluations is an important area of future research.
Assuntos
Antineoplásicos/economia , Comércio , Análise Custo-Benefício , Custos de Medicamentos , Medicamentos Genéricos/economia , Neoplasias/economia , Algoritmos , Antineoplásicos/uso terapêutico , Bortezomib/economia , Bortezomib/uso terapêutico , Dasatinibe/economia , Dasatinibe/uso terapêutico , Inglaterra , Everolimo/economia , Everolimo/uso terapêutico , Gefitinibe , Humanos , Neoplasias/tratamento farmacológico , Quinazolinas/economia , Quinazolinas/uso terapêuticoRESUMO
OBJECTIVE: To calculate sustainable generic prices for 4 tyrosine kinase inhibitors (TKIs). BACKGROUND: TKIs have proven survival benefits in the treatment of several cancers, including chronic myeloid leukaemia, breast, liver, renal and lung cancer. However, current high prices are a barrier to treatment. Mass production of low-cost generic antiretrovirals has led to over 13 million people being on HIV/AIDS treatment worldwide. This analysis estimates target prices for generic TKIs, assuming similar methods of mass production. METHODS: Four TKIs with patent expiry dates in the next 5 years were selected for analysis: imatinib, erlotinib, lapatinib and sorafenib. Chemistry, dosing, published data on per-kilogram pricing for commercial transactions of active pharmaceutical ingredient (API), and quotes from manufacturers were used to estimate costs of production. Analysis included costs of excipients, formulation, packaging, shipping and a 50% profit margin. Target prices were compared with current prices. Global numbers of patients eligible for treatment with each TKI were estimated. RESULTS: API costs per kg were $347-$746 for imatinib, $2470 for erlotinib, $4671 for lapatinib, and $3000 for sorafenib. Basing on annual dose requirements, costs of formulation/packaging and a 50% profit margin, target generic prices per person-year were $128-$216 for imatinib, $240 for erlotinib, $1450 for sorafenib, and $4020 for lapatinib. Over 1 million people would be newly eligible to start treatment with these TKIs annually. CONCLUSIONS: Mass generic production of several TKIs could achieve treatment prices in the range of $128-$4020 per person-year, versus current US prices of $75161-$139,138. Generic TKIs could allow significant savings and scaling-up of treatment globally, for over 1 million eligible patients.